This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dunn, R. L. Articles by Powers, B. E. Search for Related Content Social Bookmarking                         What's this?

Sustained Release of Cisplatin in Dogs from an Injectable Implant Delivery System

Drug Delivery Research Department, Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, CO 80525

G. L. Yewey

Drug Delivery Research Department, Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, CO 80525

S. M. Fujita

Drug Delivery Research Department, Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, CO 80525

K. R. Josephs

Drug Delivery Research Department, Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, CO 80525

S. L. Whitman

Drug Delivery Research Department, Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, CO 80525

G. L. Southard

Drug Delivery Research Department, Atrix Laboratories, Inc, 2579 Midpoint Drive, Fort Collins, CO 80525

W. S. Dernell

Comparative Oncology Unit, Colorado State University, Veterinary Teaching Hospital, Fort Collins, CO 80523

R. C. Straw

Comparative Oncology Unit, Colorado State University, Veterinary Teaching Hospital, Fort Collins, CO 80523

S. J. Withrow

Comparative Oncology Unit, Colorado State University, Veterinary Teaching Hospital, Fort Collins, CO 80523

B. E. Powers

Comparative Oncology Unit, Colorado State University, Veterinary Teaching Hospital, Fort Collins, CO 80523

Cisplatin was incorporated into an in-situ forming biodegradable implant delivery system (ATRIGELO) consisting of a biodegradable polymer dissolved in a pharmaceutically acceptable solvent. The polymer solution with the suspended cisplatin was injected subcutaneously into the flank or shoulder of six healthy beagle dogs where the water-insoluble polymer precipitated upon contact with body fluids and formed a solid implant for the controlled release of the drug. Each dog received four injections, spaced thirty days apart, of a formulation containing either poly(DL-lactide-co-caprolactone) (PLC) or pely(DL-lactide-co-glycolide) (PLGA) dissolved in dimethyl sulfoxide (DM8O) and loaded with 8% by weight cisplatin. Dosage levels of 70, 105, and 157.5 mg/m² were used to determine dosage escalation effects. Injections of the same formulations without the drug served as controls. Samples of blood were taken at appropriate times over the four months of treatment and analyzed for platinum concentration by atomic absorption spectroscopy. Local tissue and systemic toxicities were also determined. Both formulations exhibited sustained release of cisplatin with peak serum concentrations of platinum being attained in about two days followed by gradually decreasing platinum levels to day thirty. Consistent drug release profiles were observed for each of the four thirty-day treatment periods. The dosage escalation results exhibited an approximate 50% increase in peak platinum levels and area-under-the-curve (AUC) values for each 50% increase in drug dose. Local tissue toxicity to the cisplatin-containing implants was variable and appeared to be unrelated to dose level or direction number. Tissue reaction to the implants without drug was minimal indicating a role of cisplatin in the tissue reactions. Systemic toxicity, as judged by clinical parameters and clinicopathologic evaluation, was not noted at any dose level or injection time.

Journal of Bioactive and Compatible Polymers, Vol. 11, No. 4, 286-300 (1996)
DOI: 10.1177/088391159601100402


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?